The 4th International Electronic Conference on Cancers
.jpg?1714204884)
The 4th International Electronic Conference on Cancers
Part of the International Electronic Conference on Cancers (IECC) series
Event's Timezone: Central European TimeCancer Immunology and Immunotherapy, Cancer Biomarkers, Cancer Epidemiology and Prevention, Cancer Pathophysiology, Tumor Microenvironment, Transplant Oncology and Cancer Nursing Care, Cancer Therapy, Pediatric Oncology, Cancer Metastasis
Conference Closed
On behalf of the conference organizing committee of the 4th International Electronic Conference on Cancers (IECC2024), we would like to express our appreciation to all of the participants for their contributions. From all accounts, the meeting was a success.
Sharing your feedback with us is very important to improve future events. We would very much appreciate it if you could spend a couple of minutes to fill out our Satisfaction Survey.
Best Oral Presentation Award and Best Poster Award of IECC2024 are under evaluation. Please pay attention to Event Awards updates for detailed information and winner announcements.
Welcome from the Chairs
Dear Colleagues,
It is a great pleasure to welcome you to the 4th International Electronic Conference on Cancers (IECC 2024), which will be held from 6 to 8 March 2024. The conference is organized by the MDPI open-access journal Cancers (Impact Factor 5.2). It allows scientists from all over the world to present their latest research in Cancers, receive direct feedback, and engage in discussions with the wider scientific community.
In recent years, we have witnessed remarkable breakthroughs in basic cancer research, where discoveries in the genetic and epigenetic tumor make-up and tumor microenvironment have provided valuable insights into the molecular mechanisms underlying cancer initiation, progression, and therapeutic response. This newfound knowledge has laid the groundwork for novel treatment strategies and personalized approaches that hold the potential to revolutionize cancer care. This conference aspires to bring together clinicians and scientists with diverse expertise and perspectives in cancer research to interact, exchange ideas, and form new collaborations that may lead to new advancements in scientific understanding and ultimately impact patient outcomes.
This year’s conference is dedicated to following sessions:
The IECC 2024 will be an online-only proceeding, which allows participation from all over the world with no requirement for travel or related expenditures. An electronic conference provides a platform for rapid and direct exchanges about the latest research findings and novel ideas.
We are committed to equality and inclusion principles. Therefore, we ask authors to ensure that the papers and presentations are highly accessible to the wider and more diverse scientific community. We encourage submissions from scientists at all career stages and backgrounds and aim for an equal gender balance.
The conference will provide 6 awards including Best Oral Presentation Award and Best Poster Award.
We look forward to receiving your contributions to this scientific event and would like to thank you in advance for your active support.
We hope that the community will share this enthusiasm and help make this conference a success.
Sincerely,
Dr. Angeliki Magklara, Dr. Shinji Kawabata, Prof. Dr. Alfredo Conti, Professor Vasso Apostolopoulos
The chair of the 4th International Electronic Conference on Cancers
Welcome to follow us at
IECC 2024 Program
Click here to register for IECC 2024 for free! The registration includes attendance to all conference sessions.
Session G. Cancer Therapy
Session H. Cancer Pathophysiology
Session C. Cancer Immunology and Immunotherapy
Session B. Cancer Biomarkers
Session D. Tumor Microenvironment
IECC 2024 - Live Session Recordings
Book of Abstracts
Event Chairs
Laboratory of Clinical Chemistry, Faculty of Medicine, School of Health Sciences, University of Ioannina and Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Greece
Over 25 years experience in cancer immunology, cancer vaccines and drug development with translation of research findings to over 20 human phase I, II, III clinical trials. Vasso has over 500 publications, is an active researcher and has also led several research programs and senior executive University roles. She is currently at Victoria University, Australia, and leads the Immunology and Translational Research, focussing on vaccines and drugs against, cancer, metabolic diseases, infectious diseases and drug addiction. https://www.vu.edu.au/research/vasso-apostolopoulos
Unit of Neurosurgery, IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy
Session Chairs
Prof. Dr. Alfredo Conti
Unit of Neurosurgery, IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy
https://sciprofiles.com/profile/1333745?
Prof. Dr. Mario Capasso
Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università Degli Studi di Napoli, Italy
https://sciprofiles.com/profile/307072?
Prof. Dr. Vasso Apostolopoulos
Institute for Health and Sport, Victoria University, Australia
https://sciprofiles.com/profile/139297?
Prof. Dr. Robert-Alain Toillon
Univ. Lille, CNRS, Inserm, CHU Lille, UMR 9020-U 1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, France
https://sciprofiles.com/profile/2192468?
Dr. Farrukh Aqil
Department of Medicine, University of Louisville, USA
https://sciprofiles.com/profile/1208998?
Dr. Ulrich Pfeffer
Laboratory of Gene Expression Regulation, IRCCS Ospedale Policlinico San Martino, Italy
https://sciprofiles.com/profile/ulrich-pfeffer
Prof. Nicola Amodio
Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Italy
https://sciprofiles.com/profile/380363?
Prof. Stephen G. Ward
Univesity of Bath, UK
https://sciprofiles.com/profile/3099655
Prof. Giuseppe Viglietto
Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi “Magna Græcia” di Catanzaro, Campus “S. Venuta”, Viale Europa, Catanzaro, Italy
co-session chair
Event Committee
School of Chemistry and Biochemistry, Georgia Institute of Technology, USA
Interests: chemical biology; epigenetics; drug design; fibrosis; RNA–small molecule interaction
Department of Pathology, College of Medicine, University of South Alabama, USA,
Cancer Biology Program, Mitchell Cancer Institute, University of South Alabama, USA
Interests: pancreatic cancer; prostate cancer; breast cancer; carcinogenesis; tumor microenvironment; metastasis; therapy resistance; gene regulation
Capital Health Medical Center, Pennington, USA,
Department of Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia, USA,
Department of Biology, College of Science and Technology, Temple University, Philadelphia, USA
Interests: artificial intelligence applied to cancer care; the latest diagnostic and treatment options in cancer
Division of Clinical Pharmacy, Institute of Pharmaceutical and Medical Chemistry, University of Muenster, Germany
Interests: pharmacokinetics of anticancer drugs; population pharmacokinetics; bioanalysis of anticancer drugs; therapeutic drug monitoring
Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain
Interests: gastrointestinal oncology; gastric cancer; colorectal cancer; pancreatic cancer; immunotherapy; clinical trials; neuroendocrine tumors
Interests: cancer immunometabolism; cancer therapeutics; apoptosis; immunotherapy; cancer metabolism; colorectal cancer
Department of Medical, Surgery and Experimental Sciences, Division of Experimental Pathology and Oncology, University of Sassari, Italy
Interests: molecular cancer biology; cancer biomarkers; cancer epidemiology and prevention; cancer pathophysiology; tumor microenvironment; cancer causes; screening and diagnosis; clinical trials of cancer; systematic review or meta-analysis in cancer res
National Institute of Health and Medical Research (INSERM) Unit 1035, MicroRNAs in Cancer and Development (miRCADE) team, France,
2. Groupe de Recherche pour l'Etude du Foie, University of Bordeaux, Bordeaux, France
Interests: cell biology; molecular biology; developmental biology; oncology; in vivo modeling; bioinformatics; epigenetic regulation; vascular biology; angiogenesis; biomarkers; prognostic factors; chemical inhi
Head, Oncology Unit, Aretaieion University Hospital
National and Kapodistrian University of Athens, Greece
early breast cancer; adjuvant chemotherapy; chemotherapy for metastatic breast cancer; clinical trials; mTOR inhibitors; CDK4/6 inhibitors; endocrine therapy
Immuno-oncology; Inflammation; Leukocyte Biology; Signaling; Therapeutics
iBiMED-Institute of Biomedicine, Department of Medical Sciences, University of Aveiro, Aveiro, Portugal.
metabolism; mitochondria; omics; andrology; oxidative stress
LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Portugal,
CHUP, Centro Hospitalar Universitário do Porto, Porto, Portugal
medicinal and pharmaceutical sciences; infectious and cancer diseases; nanomedicine and nanotechnology; drug development and drug delivery; drug-membrane interaction studies
Keynote Speakers
School of Health and Biomedical Sciences, RMIT University, Melbourne, Australia
Title: Personalised immunotherapy and earlier diagnosis in ovarian cancer. In older age a dysfunctional immune system underlies increased susceptibility to develop cancer, this includes ovarian cancer, the most lethal gynecological malignancy. We study the immune system of across the lifespan, accounting for sex and gender, to optimise personalised immunotherapies in ovarian cancer. Moreover, we have identified new biomarkers to enable earlier cancer diagnosis, associated with greatly increased survival. Our discoveries have progressed to large scale human trials across over 20 hospitals in Australia. Currently we are also collaborating to translate our biomarker findings into practical point-of-care devices for identifying these biomarkers from a drop of blood.
Distinguished Professor Magdalena Plebanski is an internationally- renowned leader in immunology and bioengineering research, Head of the Translational Immunology and Nanotechnology Theme, and Head of the Cancer, Ageing, and Vaccines Laboratory at School of Health and Biomedical Sciences. She is also Director of RMIT’s Biomedical and Health Innovation Enabling Impact Platform. Magdalena forged a stellar career in medical and health research. At Oxford University, she showed new ways in which malaria parasites trick the human immune system and pioneered vaccine modifications now widely used around the world. Magdalena globally changed the design of nanoparticle based vaccines, showing smaller sized particles improve immune responses. Currently, Magdalena interests lie in changing the extremely low survival outcomes from ovarian cancer, by identifying new diagnostic and prognostic biomarkers in the blood. One of her patented biomarkers currently underlies a large-scale Phase II human clinical trial across 15 hospitals around Australia. Magdalena and her team are also testing innovative gold-based immunotherapies in collaboration with RMIT chemists, as well as collaborating with RMIT nanoengineers to develop practical point-of-care diagnostic devices. Magdalena has published more than 200 peer-reviewed full-length papers, including in leading journals such as Lancet, Nature, Science, Immunity, Nature Biotechnology, Nature Medicine and Nature Communications among others. University Link: https://www.rmit.edu.au/contact/staff-contacts/academic-staff/p/plebanski-magdalena Linkedin: https://www.linkedin.com/in/magdalenaplebanski/ Google Scholar: https://scholar.google.co.in/citations?user=hMyXlrMAAAAJ&hl=en
Title: The role of neuro-immune interaction in colorectal cancer development, progression and treatment. Although the immune and vascular systems have been shown to have strong influences on cancer, the role of the nervous system in the regulation of cancer development is less understood. Compelling data suggest bi-directional signaling between the nervous system and the tumor microenvironment via the release of neurotransmitters, neuropeptides, and other factors implicating their role in tumor formation, growth, and metastasis. These neurological factors play an essential role in the activation of signaling pathways influencing cancer cell proliferation, invasion, migration, and avoidance of immune surveillance. Current studies have reported that sympathetic and parasympathetic nerve fibers from the autonomic nervous system infiltrate tumours and contribute to the early stages of cancer development, as well as tumor growth, angiogenesis, and metastasis. In addition, cancer cells express receptors for various neurotransmitters, release acetylcholine and cytokines, which alter immune responses. Moreover, chemotherapy and immunotherapy have significant adverse effects on the nervous system. This presentation will discuss the emerging role of the nervous system and neuro-immune interaction in creating a favourable microenvironment for the progression of cancer.
Professor Kulmira Nurgali (PhD 2004, Melbourne University) is a research and teaching academic at the College of Health and Engineering, Institute for Health and Sport, Victoria University, Australia and an Honorary Associate Professor at the Department of Medicine, University of Melbourne, Australia. She is the Head of Enteric Neuropathy Laboratory at the Centre for Health, Research and Education, Sunshine Hospital, Melbourne, Australia and Director of the Stem Cells and Regenerative Medicine Program at the Australian Institute for Musculoskeletal Science. She has an internationally-recognized prominence in the fields of Enteric Neuroscience and Neurogastroenterology. Prof Nurgali’s research is focused on enteric neuropathy associated with Inflammatory Bowel Disease, colorectal cancer, and the side effects of chemotherapy. Being a medical graduate, she focuses on the development of novel treatments and pre-clinical studies that have translational value. Publications and research activity can be found via ORCID ID: 0000-0002-2597-6929. University Link: https://www.vu.edu.au/contact-us/kulmira-nurgali Linkedin: https://www.linkedin.com/in/kulmira-nurgali-82291124/ Google Scholar: https://scholar.google.co.in/citations?hl=en&user=oVtmgcgAAAAJ
Invited Speakers
SESSION G. Cancer Therapy Topic: Epigenetic drugs to improve efficacy of immune checkpoint blocker therapy
Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi (Salerno), Italy
SESSION G. Cancer Therapy Topic: Targeting chromatin remodelers to overcome endocrine therapy resistance in breast cancer
Breast Biology Group, Manchester Breast Centre, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, United Kingdom
SESSION H. Cancer Pathophysiology (Sub-Session 1: Overcoming drug resistance). Topic:Targeting cancer stem cells in hormone-resistant breast cancer
Candiolo Cancer Institute-IRCCS-FPO, Italy
SESSION H. Cancer Pathophysiology (Sub-Session 1: Overcoming drug resistance) Topic Title: Dissecting the path to immunogenic chemotherapy in multiple myeloma
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Italy
SESSION H. Cancer Pathophysiology (Sub-Session 1: Overcoming drug resistance). Topic Title: A hybrid cell population generated through engulfment of mesenchymal stem cell by breast cancer cells enhances chemoresistance and metastasis
Bing Center for Waldenström Macroglobulinemia, Dana Farber Cancer Institute, USA
Department of Medicine, Harvard Medical School, USA
Session: SESSION H. Cancer Pathophysiology (Sub-Session 2: Dissecting tumor heterogeneity). Title: Multi-omic Analysis of Clonal Evolution and the Subtypes of Waldenstrom's Macroglobulinemia
SESSION H. Cancer Pathophysiology (Sub Session 2: Dissecting tumor heterogeneity). Title: ncRNA deregulation as a flag of drug resistance in HER2-positive breast cancer
Centre for Therapeutic Innovation, Cell Biophysics Laboratory, Faculty of Science, University of Bath, UK
SESSION E. Molecular Cancer Biology. Title: The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeutic.
SESSION C. Cancer Immunology and Immunotherapy. Title: ROLE OF NLRP3 INFLAMMASOME COLITIS-ASSOCIATED COLORECTAL CANCER
SESSION C. Cancer Immunology and Immunotherapy. Title: Cancer Immunotherapy three ways.
SESSION C. Cancer Immunology and Immunotherapy. Title: Targeting Gliomas.
SESSION C. Cancer Immunology and Immunotherapy. Title: NEW THERAGNOSTIC AGENT AGAINST GLIOMA BASED ON GEMCITABINE
SESSION C. Cancer Immunology and Immunotherapy. Title: CAR T Cell therapy for the management of mantle cell lymphoma.
Recherche Translationelle en Oncologie Pédiatrique (RTOP), INSERM U830 Cancer, Heterogeneity, Instability and Plasticity, Department of Translational Research, Institut Curie Research Center, PSL Research University, France,
SIREDO Integrated Pediatric Oncology Center, Institut Curie Hospital Group, France
SESSION B: Cancer Biomarkers.
Department of Laboratory Medicine, Translational Cancer Research, Faculty of Medicine, Lund University, Sweden
SESSION B: Cancer Biomarkers.
Topic title: Unlocking the Future of Lung Cancer Treatment: Biomarkers and Preclinical Insights
Hematology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy
The Dynamic myeloma microenvironment: implications for cancer evolution and therapy resistance
Instructions for Authors
IECC 2024 will accept abstracts only. The accepted abstracts will be available online on Sciforum.net during and after the conference.
Important Deadlines
- Deadline for abstract submission:
7th November 202315th December 2023. - Announcement of oral and poster abstract results:
7th December 202320th January 2024. You will be notified of the acceptance of an oral/poster presentation in a separate email.
Abstract Submission
Abstract submissions should be completed online by registering with www.sciforum.net and using the "New Submission" function once logged into the system. No physical template is necessary.
- The abstract should include the introduction, methods, results, and conclusions sections of about 200–300 words in length.
- All accepted abstracts will be published as one dedicated volume (Conference Report) in MDPI’s Proceedings journal (ISSN 2673-9992). If you wish to publish a proceedings paper or a research article in the journal, please refer to the “Publication Opportunities” Section.
- All abstracts should be submitted and presented in clear, publication-ready English with accurate grammar and spelling.
- You may submit multiple abstracts. However, only one abstract will be selected for oral presentation.
Detailed Requirements:
1. The submitting author must ensure that all co-authors are aware of the contents of the abstract.
2. Please select only one presenter for each submission. If you would like to change the presenter after submission, please email us accordingly.
Note: We only accept live presentations.
Oral Presentation and Slides Submission
The slot for the oral presentation is 15 mins. We advise that your presentation lasts for a maximum of 12 mins, leaving at least 3 mins for the Q&A session.
Authors are encouraged to prepare a presentation in PowerPoint or similar software, to be displayed online along with the abstract. Slides, if available, will be displayed directly on the website using the proprietary slide viewer at Sciforum.net. Slides can be prepared in exactly the same way as for any traditional conference where research results are presented. Slides should be converted to PDF format before submission so that they can be converted for online display.
Poster
· Should include the title, authors, contact details, and main research findings, as well as tables, figures, and graphs where necessary.
· File format: PDF (.pdf).
· Size in pixel: 1,080 width x 1,536 height–portrait orientation.
· Size in cm: 38.1 width x 54.2 height–portrait orientation.
· Font size: ≥16.
Examples of successful submissions can be viewed here at the following links: (1), (2), (3)
You can use our free template to create your poster. The poster template can be downloaded here.
The Poster Sessions will take place in Zoom break-out rooms. The rooms will be called after your surname. You will automatically be assigned to your break-out room, however, you will be responsible for your own room, i.e. sharing your screen by yourself, handling the comments in the chat if there are any, etc. People will then be able to visit your room and discuss your poster with you. Please make sure you have the Zoom Desktop client or mobile app, version 5.3.0 or higher.
We will reach out to you closer to the dates of the conference with more information.
Publication Opportunities
- Cancers Journal Publication
Participants in this conference are cordially invited to contribute a research article to the Special Issue published in Cancers (ISSN: 2072-6694, IF 5.2), with a 20% discount on the publication fee. Please note that no other discounts are applicable. All submitted papers will undergo MDPI’s standard peer-review procedure. The abstracts should be cited and noted on the first page of the paper.
- Proceeding Paper Publication
You are welcome to submit a proceeding paper (4-8 pages) to Medical Sciences Forum (ISSN: 2673-9992) after the conference.
Publication of the proceedings will be free of charge.
Authors are asked to disclose that it is a proceeding paper of the IECC2024 conference paper in their cover letter.
Please Submit your manuscript from 8 March to 19 April 2024.
Carefully read the rules outlined in the 'Instructions for Authors' on the journal’s website and ensure that your submission adheres to these guidelines.
Manuscripts for the proceedings issue must be formatted as follows:
- Title.
- Full author names.
- Affiliations (including full postal address) and authors' e-mail addresses.
- Abstract.
- Keywords.
- Introduction.
- Methods.
- Results and Discussion.
- Conclusions.
- Acknowledgements.
- References.
Note : Publication of proceedings paper is free of charge.
Potential Conflicts of Interest
It is the authors' responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state "The authors declare no conflicts of interest." This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Any financial support for the study must be fully disclosed in the "Acknowledgments" section.
Copyright
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe authors should retain the copyright to their scholarly works. Hence, by submitting an abstract to this conference, you retain the copyright to the work, but you grant MDPI the non-exclusive right to publish this abstract online on the Sciforum.net platform. This means you can easily submit your full paper (with the abstract) to any scientific journal at a later stage and transfer the copyright to its publisher if required.
List of Authors (241)
.png)
Event Awards
To acknowledge the support of the conference's esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to announce that the conference will provide 6 awards including Best Oral Presentation Award and Best Poster Award.
The Awards
Number of Awards Available: 6
The Best Oral Presentation Award is given to the paper judged to make the most significant oral contribution to the conference.
The Best Poster Award is given to the submission judged to make the most significant and interesting poster for the conference.
There will be six winners selected for this award. The winner will receive a certificate and 200 CHF each.
Sponsors and Partners
For information regarding sponsorship and exhibition opportunities, please click here.
Organizers
Media Partners
Conference Secretariat
Ms. Simon You
Ms. Wynne Yang
Ms. Ariel Zhang
E-Mail: iecc2024@mdpi.com
For inquiries regarding submissions and sponsorship opportunities, please feel free to contact us.
